CAR-T cell therapy for blood cancers that have returned
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a newer type of immune therapy called CAR-T cells in people with blood cancers like AML or MDS that have come back or not responded to prior treatments. The therapy is designed to find and destroy cancer cells that have specific markers (CD33, CD123, or CLL-1), with the goal of putting the cancer into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have a blood cancer like AML or MDS that has returned or hasn't responded to at least two rounds of treatment
- Your cancer cells show certain markers (CD33, CD123, or CLL-1) that the therapy targets
- You are expected to live at least 3 months and are in reasonably good health (heart, liver, kidneys functioning well)
- You have not had a recent stem cell transplant with complications like graft-versus-host disease or are not on immune-suppressing drugs for it
- You do not have uncontrolled infections like HIV, active hepatitis B or C, or untreated syphilis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Hear when a new CAR-T trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.